Single antiplatelet therapy — Competitive Intelligence Brief

Single antiplatelet therapy (Single antiplatelet therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent. Area: Cardiovascular.

marketed Antiplatelet agent Cardiovascular Small molecule

Target snapshot

Single antiplatelet therapy (Single antiplatelet therapy) — China National Center for Cardiovascular Diseases. Single antiplatelet therapy inhibits platelet aggregation to reduce thrombotic events in cardiovascular disease.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Single antiplatelet therapy TARGET	Single antiplatelet therapy	China National Center for Cardiovascular Diseases	marketed	Antiplatelet agent
Plavix	clopidogrel	Generic (originally Sanofi/BMS)	marketed	Thienopyridine antiplatelet agent	Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter	1997-11-17
Aspirin	acetylsalicylic acid	Bayer AG	marketed	NSAID, Antiplatelet agent	Gamma-glutamyltranspeptidase 1, Nicotinate phosphoribosyltransferase, Acid-sensing ion channel 3	1899-03-06
Crushed ticagrelor, morphine,metoclopramide	Crushed ticagrelor, morphine,metoclopramide	Collegium Medicum w Bydgoszczy	marketed	Antiplatelet agent + opioid analgesic + antiemetic (combination therapy)	P2Y12 receptor (ticagrelor); mu opioid receptors (morphine); dopamine D2 receptors (metoclopramide)
Aspirin and thienopyridine	Aspirin and thienopyridine	Associations for Establishment of Evidence in Interventions	marketed	Dual antiplatelet agent combination	COX-1 (aspirin); P2Y12 receptor (thienopyridine)
clopidogrel bisulfate + aspirin	clopidogrel bisulfate + aspirin	Seoul National University Hospital	marketed	Dual antiplatelet agent	P2Y12 receptor (clopidogrel); cyclooxygenase (aspirin)
Clopidogrel treatment	Clopidogrel treatment	VA Office of Research and Development	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent class)

1. Asan Medical Center · 1 drug in this class
2. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
3. Beijing Tiantan Hospital · 1 drug in this class
4. Centre Hospitalier Universitaire de Saint Etienne · 1 drug in this class
5. China National Center for Cardiovascular Diseases · 1 drug in this class
6. Hospital Israelita Albert Einstein · 1 drug in this class
7. Icahn School of Medicine at Mount Sinai · 1 drug in this class
8. PLx Pharma · 1 drug in this class
9. Sichuan Provincial People's Hospital · 1 drug in this class
10. The George Institute for Global Health, China · 1 drug in this class